Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Cancer Discov. 2022 Mar 1;12(3):606–624. doi: 10.1158/2159-8290.CD-21-0212

Figure 3: Different cancer drugs benefit different patients in a population.

Figure 3:

Responses to different single drugs can be measured in the same tumor (as duration of progression-free survival) through (A, B) patient-derived tumor xenografts(73), or (C) human patients treated with sequential monotherapy(77). None of these drug pairs have a statistically significant correlation in response duration (as determined by a Spearman’s rank test). Patients and xenografts are sorted based on response to the single agent depicted in green.